Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Allergan PLC, consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Cash and cash equivalents 999,500 2,503,300 1,237,500 1,651,400 788,500 880,400 1,187,900 1,674,700 994,800 1,817,200 1,612,700 886,900 1,092,900 1,724,000 7,554,700 489,500 2,260,800 1,096,000 2,063,900 1,517,900 2,114,900
Marketable securities 1,618,800 3,411,600 3,318,400 322,300 995,200 1,026,900 22,000 21,500 1,037,400 4,632,100 3,829,100 4,939,000 7,858,200 11,501,500 19,837,600 17,100 13,000 9,300 7,000 8,500 16,000
Accounts receivable, net of allowances for doubtful accounts and credit losses 2,800,600 3,192,300 3,012,300 3,086,300 2,731,200 2,868,100 2,826,900 2,760,800 2,639,200 2,899,000 2,808,600 2,795,900 2,542,000 2,531,000 2,398,500 2,490,500 2,652,800 2,401,600 2,143,200 4,420,100 3,992,800
Inventories 1,199,900 1,133,100 1,083,100 1,004,500 943,200 846,900 894,600 922,500 948,400 904,500 899,800 935,900 904,700 718,000 705,500 726,800 1,022,200 1,009,700 1,285,400 2,786,000 3,125,100
Current assets held for sale — — — — 45,700 34,000 7,300 — — — — — — — 455,900 4,244,000 3,508,400 3,540,300 3,802,100 38,000 143,500
Prepaid expenses and other current assets 855,300 886,400 942,300 2,508,300 785,500 819,100 801,500 724,200 773,500 1,123,900 962,600 875,500 1,302,900 1,383,400 771,700 787,300 634,300 558,500 748,600 1,004,800 1,024,100
Deferred tax assets — — — — — — — — — — — — — — — — — — 6,608,500 711,600 600,800
Current assets 7,474,100 11,126,700 9,593,600 8,572,800 6,289,300 6,475,400 5,740,200 6,103,700 6,393,300 11,376,700 10,112,800 10,433,200 13,700,700 17,857,900 31,723,900 8,755,200 10,091,500 8,615,400 16,658,700 10,486,900 11,017,200
Property, plant and equipment, net 1,915,400 1,926,500 1,857,000 1,821,000 1,781,100 1,787,000 1,756,600 1,761,400 1,769,500 1,785,400 1,802,200 1,750,100 1,659,300 1,611,300 1,566,300 1,557,200 1,602,400 1,573,900 1,569,900 2,859,000 2,797,900
Right of use asset, operating leases 481,000 490,400 478,200 457,900 455,400 — — — — — — — — — — — — — — — —
Investments and other assets 430,700 408,000 367,900 335,200 1,979,500 1,970,600 302,800 297,900 267,100 267,900 269,900 290,200 283,200 282,100 341,100 352,600 405,500 577,400 498,300 530,300 518,300
Non current assets held for sale 31,700 31,700 32,500 32,500 897,200 882,200 169,700 180,400 71,800 81,600 11,100 11,100 27,000 27,000 207,200 10,798,000 10,636,800 10,541,300 10,573,700 — —
Deferred tax assets 597,900 576,900 487,400 689,100 1,032,600 1,063,700 989,400 899,900 893,600 319,100 327,000 288,300 255,400 233,300 120,700 179,500 77,700 49,500 67,200 113,600 99,800
Product rights and other intangibles 36,266,200 37,890,600 39,526,800 41,231,500 42,264,600 43,695,400 48,127,400 49,928,300 52,566,500 54,648,300 56,698,900 62,369,700 62,994,200 62,618,600 63,022,700 64,460,800 66,535,800 67,931,700 67,133,400 72,825,000 74,201,100
Goodwill 41,229,200 42,248,300 42,065,500 42,340,700 43,336,600 45,913,300 49,456,400 49,687,200 50,059,500 49,862,900 49,770,900 49,592,200 47,917,100 46,356,100 46,625,800 46,515,800 46,724,000 46,551,500 46,315,100 51,596,300 50,826,400
Non current assets 80,952,100 83,572,400 84,815,300 86,907,900 91,747,000 95,312,200 100,802,300 102,755,100 105,628,000 106,965,200 108,880,000 114,301,600 113,136,200 111,128,400 111,883,800 123,863,900 125,982,200 127,225,300 126,157,600 127,924,200 128,443,500
Total assets 88,426,200 94,699,100 94,408,900 95,480,700 98,036,300 101,787,600 106,542,500 108,858,800 112,021,300 118,341,900 118,992,800 124,734,800 126,836,900 128,986,300 143,607,700 132,619,100 136,073,700 135,840,700 142,816,300 138,411,100 139,460,700

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Allergan PLC current assets increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Property, plant and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Allergan PLC property, plant and equipment, net increased from Q3 2019 to Q4 2019 but then slightly decreased from Q4 2019 to Q1 2020.
Non current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Allergan PLC non current assets decreased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Allergan PLC total assets increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Allergan PLC cash and cash equivalents increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Marketable securities Amount of investment in marketable security, classified as current. Allergan PLC marketable securities increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Accounts receivable, net of allowances for doubtful accounts and credit losses Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Allergan PLC accounts receivable, net of allowances for doubtful accounts and credit losses increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Allergan PLC inventories increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.